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Background. Outcome data from prospective follow-up studies comparing infections with different influenza virus types/sub-
types are limited.
Methods. Demographic, clinical characteristics and follow-up outcomes for adults with laboratory-confirmed influenza 
A(H1N1)pdm09, A(H3N2), or B virus infections were compared in 2 prospective cohorts enrolled globally from 2009 through 2015. 
Logistic regression was used to compare outcomes among influenza virus type/subtypes.
Results. Of 3952 outpatients, 1290 (32.6%) had A(H1N1)pdm09 virus infection, 1857 (47.0%) had A(H3N2), and 805 (20.4%) 
had influenza B. Of 1398 inpatients, 641 (45.8%) had A(H1N1)pdm09, 532 (38.1%) had A(H3N2), and 225 (16.1%) had influenza 
B. Outpatients with A(H1N1)pdm09 were younger with fewer comorbidities and were more likely to be hospitalized during the 
14-day follow-up (3.3%) than influenza B (2.2%) or A(H3N2) (0.7%; P < .0001). Hospitalized patients with A(H1N1)pdm09 (20.3%) 
were more likely to be enrolled from intensive care units (ICUs) than those with A(H3N2) (11.3%) or B (9.8%; P < .0001). However, 
60-day follow-up of discharged inpatients showed no difference in disease progression (P =  .32) or all-cause mortality (P =  .30) 
among influenza types/subtypes. These findings were consistent after covariate adjustment, in sensitivity analyses, and for subgroups 
defined by age, enrollment location, and comorbidities.
Conclusions. Outpatients infected with influenza A(H1N1)pdm09 or influenza B were more likely to be hospitalized than those 
with A(H3N2). Hospitalized patients infected with A(H1N1)pdm09 were younger and more likely to have severe disease at study 
entry (measured by ICU enrollment), but did not have worse 60-day outcomes.
Keywords. follow-up; influenza A(H1N1)pdm09; influenza A(H3N2); influenza B; outcomes.
 
Influenza A(H1N1)pdm09 virus emerged in 2009 [1], and 
it now co-circulates with influenza B and A(H3N2) viruses. 
Comparisons of different influenza types/influenza A subtype 
infections are useful to understand clinical outcome variations, 
including intensive care unit (ICU) admission, mortality, and 
severity predictors. Ideally, such data would come from fol-
low-up studies of geographically diverse populations enrolled 
over multiple successive influenza seasons. In addition to assist-
ing clinical management and preparedness responses, such data 
could inform clinical trial design for new therapeutics.
Several studies describe the clinical characteristics, hospital 
admission rates, and severity of hospitalized cases for patients 
with laboratory-confirmed influenza by virus type/subtype [2–
6]. US population–based hospitalization surveillance reported 
that adults with influenza A(H1N1)pdm09 were more likely to 
require ICU admission than those with A(H3N2) or B, although 
mortality did not vary [2, 3]. Neither ICU admission nor mor-
tality differed by virus type/subtype among French inpatients 
[4]. In 30-day follow-up of outpatients in Wisconsin, hospital-
ization for both adults and children with influenza A vs B [5] 
and with A(H1N1)pdm09 vs A(H3N2) [6] were similar. These 
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studies were limited by sample size; the outpatient studies only 
enrolled from 1 region.
To compare demographics, clinical characteristics and fol-
low-up outcomes for adults infected with influenza A(H1N1)
pdm09, A(H3N2), or B viruses, data from 2 prospective, con-
current, multicenter inpatient and outpatient cohorts were 
analyzed. The studies enrolled in northern and southern hemi-
sphere sites from 2009 through 2015, with laboratory confirma-
tion of influenza virus type/subtype, thus allowing comparison 
of infections over multiple seasons and locations.
MATERIALS AND METHODS
In 2009, the International Network for Strategic Initiatives in 
Global HIV Trials (INSIGHT) initiated 2 international obser-
vational cohort studies for adults aged ≥18 years with influenza 
A(H1N1)pdm09 virus infection: FLU002 for outpatients with 
influenza-like illness (ILI) and FLU003 for individuals hospi-
talized with complications and enrolled from either the general 
ward or the ICU [7, 8]. Protocols were amended to include other 
influenza viruses (June 2011), and in October 2013 FLU003 
was amended to remove the eligibility requirement of having 
severe or complicated influenza at enrollment. Some sites chose 
to enroll only outpatients or inpatients. Institutional review 
boards approved the protocols, and individual signed informed 
consent was obtained.
Enrollment nasal/oropharyngeal swabs were collected and 
sent to central laboratories (Leidos, MD; ABML, NJ) for influ-
enza A(H1N1)pdm09, A(H3N2), and B virus testing by reverse 
transcriptase polymerase chain reaction (RT-PCR). Only 
RT-PCR-confirmed influenza infections were analyzed [8].
FLU002 outpatients had 14-day follow-up for death and hos-
pitalization. FLU003 inpatients had a 60-day follow-up, with 
disease progression outcomes defined differently for general 
ward (death, hospitalization ≥28 days, ICU admission, or use of 
mechanical ventilation during follow-up) and ICU enrollments 
(death or hospitalization ≥28 days).
Statistical Analysis
Logistic regression was used to compare risk of disease pro-
gression outcomes among influenza type/subtypes. Crude and 
adjusted odds ratios (ORs) and 95% confidence intervals were 
derived using A(H1N1)pdm09 as the reference group. For 
FLU002 adjusted analyses, baseline covariates were age, gen-
der, ethnicity, geographic region, symptom duration ≥6 days at 
enrollment, body mass index (BMI), smoking status, influenza 
vaccination in the season pre-enrollment (note that this study 
was not designed to assess vaccine efficacy), antiviral usage, 
and the presence of at least 1 of the following clinician-defined 
comorbidities: asthma/chronic obstructive pulmonary dis-
ease, immunosuppression, cardiovascular/liver/renal disease, 
or diabetes. Covariates significant in univariate analyses for 
FLU002 were retained for additional multivariable analysis in 
a parsimonious model. Covariates that remained significant in 
multivariable analysis were also considered for potential effect 
modification, ie, whether type/subtype differences varied by 
the significant predictor of outcome (for these, the interaction 
P value is cited).
FLU003 used the same covariates, along with the presence of 
at least 1 complication that initially defined enrollment eligibil-
ity. Crude and adjusted ORs were estimated for ward and ICU 
enrollments, separately and overall. For the latter, unadjusted 
and adjusted analyses were stratified according to ICU or gen-
eral ward enrollment.
Sensitivity analyses were performed for both cohorts: 1 
restricted to those enrolled post-April 2012 when all 3 viruses 
were co-circulating (to minimize confounding that might 
arise from combining analyses across seasons) and a second 
restricted to sites that enrolled at least 1 patient with each type/
subtype. For FLU003, a sensitivity analysis was carried out for 
baseline and outcome variables in which viruses were compared 
for the time pre/post the October 2013 protocol amendment.
Following a significant (P < .05) omnibus test for virus differ-
ences in disease progression outcomes, pairwise comparisons 
of viruses were considered significant if the (2-sided) P value 
was less than .05. To reduce type 1 error risk for type/subtype 
comparisons for baseline characteristics, a P value for the omni-
bus test of .01 was used to assess the significance (P <  .01) of 
pairwise comparisons. Analyses used SAS v.  9.4 (Statistical 
Analysis Software, Cary NC).
RESULTS
Over 6  years from October 2009 through September 2015, 
each year reflecting 1 northern and southern hemisphere win-
ter, there were 5350 enrollments (3952 outpatients and 1398 
inpatients) with laboratory-confirmed influenza: 1931 with 
A(H1N1)pdm09, 2389 with A(H3N2), and 1030 with influenza 
B.  Initial seasons were dominated by A(H1N1)pdm09; 2011–
2012 were dominated by A(H3N2), followed by substantial 
co-circulation of the 3 viruses (Figure 1).
In FLU002, 89 sites in 17 countries enrolled 9555 outpatients 
with ILI; 3952 (41.4%) were central laboratory-confirmed: 1290 
(32.6%) with A(H1N1)pdm09, 1857 (47.0%) with A(H3N2), 
and 805 (20.4%) with B (Table 1, Supplementary Figure S1).
In FLU003, 87 sites (50 also participated in FLU002) in 16 coun-
tries enrolled 2170 patients hospitalized with suspected influenza; 
1398 (64.4%) patients had laboratory-confirmed influenza: 641 
(45.8%) with A(H1N1)pdm09, 532 (38.1%) with A(H3N2), and 
225 (16.1%) with B (Table 1, Supplementary Figure S2). One thou-
sand one hundred eighty-six (84.8%) were enrolled in the general 
ward, and 212 (15.2%) were enrolled in the ICU.
FLU002 Outpatient Cohort Baseline Characteristics
The median age of outpatients with A(H1N1)pdm09 was 
35  years, compared with 39  years for those with A(H3N2) 
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(P < .0001) and 42 years with B (P < .0001; P < .0001 also for 
A(H3N2) vs B). Most outpatients were enrolled within 3 days 
of ILI onset. This varied significantly among types/subtypes 
(P < .0001): More influenza B–infected outpatients were enrolled 
4–5 days or ≥6 days from symptom onset than A(H1N1)pdm09 
(P < .0001) or A(H3N2) (P < .0001) infections. Comorbidities 
were common, and more frequent in influenza B virus infection 
than A(H1N1)pdm09 (P = .0009) or A(H3N2) (P = .01). This 
difference was largely due to a greater percentage of immuno-
suppressed outpatients with influenza B (P = .0002) (Table 1). 
Age differences among type/subtypes persisted (P < .0001) after 
adjustment for other factors in Table 1; differences in the preva-
lence of comorbidities were reduced (P = .09 after adjustment).
FLU003 Inpatient Cohort Baseline Characteristics
Tables 1 and Supplementary Table S1 summarize baseline char-
acteristics for the 1398 hospitalized patients, which were similar 
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Figure 1. Prevalence of influenza virus type/influenza A virus subtypes, October 
2009 through September 2015.
Table 1. Baseline Characteristics of FLU002 Outpatient and FLU003 Inpatient Cohort Enrollments and Influenza Virus Type/Influenza A Virus Subtype
FLU002 (N = 3952) FLU003 (N = 1398)
A(H1N1)pdm09 A(H3N2) B A(H1N1)pdm09 A(H3N2) B
Characteristics n = 1290 n = 1857 n = 805 P Valuea n = 641 n = 532 n = 225 P Valuea
Age, median (25th, 75th), y 35 (27, 47) 39 (30, 51) 42 (34, 53) <.0001 49 (36, 61) 67 (49, 77) 59 (45, 71) <.0001
18–34, % 50.9 39.3 28.7 <.0001 22.4 13.4 12.0 <.0001
35–49, % 30.7 34.0 40.3 30.3 12.2 19.1
50–64, % 15.7 19.6 25.6 32.5 19.9 32.9
65+, % 2.6 7.0 5.5 14.8 54.5 36.0
Female, % 52.7 52.8 49.9 .36 53.2 51.9 52.4 .71
Raceb <.0001 .08
Asian, % 26.7 19.5 20.0 11.1 16.7 13.8
Black, % 4.6 3.3 3.4 7.3 9.0 7.6
White/other, % 68.7 77.1 76.6 81.6 74.2 78.7
BMI, median (25th, 75th),  
kg/m2
24.6 (21.8,  
28.1)
24.8 (22.0, 
28.1)
25.1 (22.5, 
28.8)
.03 26.2 (23.0,  
30.6)
26.3 (22.7, 
31.3)
26.0 (22.9, 
30.5)
.62
Smoker, % 19.3 17.9 21.4 .12 29.4 16.3 19.1 <.0001
Pregnant, % of women  
aged ≤45 y
3.3 3.7 3.5 .94 24.8 23.5 38.5 .16
Vaccination in past 12 mo, % 13.9 19.1 16.0 .0005 26.2 49.6 36.4 <.0001
Antiviral therapy, % 1.9 1.0 0.7 .03 79.9 78.0 70.7 .03
Time since symptom onset, d <.0001 <.0001
0–3 d 84.8 87.6 77.1 21.9 35.7 22.8
4–5 d 10.5 9.2 15.0 24.3 26.1 24.2
≥6 d 4.6 3.2 7.8 53.8 38.2 53.0
Comorbidities
Asthma/COPD, % 5.9 5.5 4.1 .19 30.3 38.9 28.4 .003
Diabetes, % 3.5 3.7 4.3 .58 12.8 23.9 16.4 <.0001
CVD/liver/renal disease, % 2.8 3.7 4.8 .05 21.5 38.9 34.7 <.0001
HIV/other immune  
dysfunction, %
10.1 11.5 16.0 .0002 14.0 11.3 16.9 .10
Any of above, % 19.5 21.2 25.7 .003 54.4 73.5 65.3 <.0001
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease.
aBaseline characteristics for influenza types/subtypes were compared in each study using the 2 degrees of freedom chi-square test for categorical statistics and Kruskal-Wallis rank for 
continuous variables. For FLU 003, P values are with stratification by ward at enrollment.
bIn FLU002, Asian sites enrolled 20% of patients, Australia 1%, Europe 29%, South America 42%, and North America (USA) 9%. In FLU003, Asian sites enrolled 11% of patients, 
Australia 13%, Europe 44%, South America 9%, and North America (USA) 23%.
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for ward (1186) and ICU (212) enrollments. The median time 
from hospitalization to enrollment was 2  days for ward and 
3 days for ICU enrollments. ICU patients included those admit-
ted directly or general ward transfers (74/212, 34.9%).
Compared with FLU002 outpatients, FLU003 inpatients were 
older with more underlying comorbidities (Table  1). Among 
hospitalizations, those with A(H1N1)pdm09 were younger 
(49 years) than A(H3N2) (67 years; P <  .0001) or influenza B 
(59 years; P < .0001). The time from symptom onset to hospitali-
zation and enrollment varied significantly among types/subtypes 
(P < .0001), with more A(H3N2) patients enrolled within 6 days 
of symptoms onset than with A(H1N1)pdm09 (P < .0001) or B 
(P  =  .0003). Differences in age among type/subtype persisted 
(P < .0001) after adjustment for other factors in Table 1.
Percentages of hospitalized patients with comorbidities 
varied by virus (P  <  .0001). More patients with A(H3N2) 
(P < .0001) or B (P = .007) had comorbidities than those with 
A(H1N1)pdm09. This partially reflected age differences; after 
age adjustment, a significant difference remained in the percent-
age with comorbidities between A(H1N1)pdm09 and A(H3N2) 
(P = .0009), but not between A(H1N1)pdm09 and B (P = .36). 
With adjustment for all of the factors in Table 1, the difference 
among type/subtypes in the prevalence with comorbidities was 
no longer significant (P = .16).
Overall, and among hospital ward–enrolled patients, the 
percentage with complications varied among types/subtypes 
(P  <  .0001): More inpatients with A(H1N1)pdm09 had com-
plications compared with those with A(H3N2) (P < .0001) or B 
(P < .0001) (Supplementary Table S2). In part, the greater per-
centage of A(H1N1)pdm09 inpatients with complications arose 
because the initial A(H1N1)pdm09-focused protocol required 
at least 1 complication to be present at enrollment. When this 
requirement was removed in October 2013, there were no sig-
nificant differences in percentages of patients with complica-
tions by virus type/subtype. Suspected bacterial pneumonia was 
more common among all patients with A(H1N1)pdm09 virus 
infection (P = .001) (Supplementary Table S2).
Over 6 years, more A(H1N1)pdm09 patients were enrolled 
from the ICU (20.3%) than those with A(H3N2) (11.3%; 
P < .0001) or B (9.8%; P = .0004): This was evident both before 
and after the October 2013 protocol change, and was signifi-
cant after this change (P  =  .0003) (Table  2). This trend was 
also evident for seasons from April 2012 when all viruses were 
co-circulating (18.4% for A(H1N1)pdm09, 10.6% for A(H3N2), 
and 9.6% for B; P = .004).
Other factors associated with ICU enrollment were female 
gender, symptom duration ≥6  days, the presence of compli-
cations, and continent of enrollment (there were more ICU 
admissions in North and South America). When these factors 
and calendar period of enrollment were taken into account, 
the adjusted ORs of ICU enrollment for A(H3N2) vs A(H1N1)
pdm09, B vs A(H1N1)pdm09, and A(H3N2) vs B were 0.49 
(95% confidence interval [CI], 0.33–0.72; P = .0003), 0.48 (95% 
CI, 0.29–0.81; P = .005), and 1.01 (95% CI, 0.58–1.75; P = .97), 
respectively.
FLU002 Outpatient Cohort Day-14 Composite Outcomes
Overall, 3787 enrolled outpatients (95.8%) had known hos-
pitalization status at day 14 postenrollment (Supplementary 
Figure S1). The percentage hospitalized or dying within 14 days 
varied significantly among types/subtypes (P < .0001): 3.4% for 
A(H1N1)pdm09, 0.7% for A(H3N2), and 2.2% for B (Table 3).
Compared with A(H1N1)pdm09, the unadjusted ORs of 
progressing to death or hospitalization were 0.21 for outpatients 
with A(H3N2) (95% CI, 0.11–0.39; P < .0001), and 0.64 (95% 
CI, 0.36–1.14; P = 0.13) for patients with influenza B. The OR 
for patients with A(H3N2) vs B was 0.32 (95% CI, 0.16–0.67; 
P  =  .002). The OR adjusted for age, comorbidities, and geo-
graphic region for A(H3N2) vs A(H1N1)pdm09 was 0.25 (95% 
CI, 0.13–0.48; P < .0001), for B vs A(H1N1)pdm09 it was 0.65 
(95% CI, 0.35–1.17; P = .15), and for A(H3N2) vs B it was 0.39 
(95% CI, 0.19–0.82; P = .01).
Of covariates considered in adjusted analyses, older age 
(P < .01), the presence of ≥1 comorbidities (P = .002), and con-
tinent of enrollment (Australia/Asia, North America, Europe, 
South America; P <  .0001) were significantly related to death 
or hospitalization in both univariate and fully adjusted analy-
ses. For each of the subgroups defined by these baseline factors, 
outpatients with A(H1N1)pdm09 were more likely to be hos-
pitalized. Among older outpatients, the difference among type/
subtypes was reduced, leading to a significant age interaction 
(P = .03) (Table S3).
A sensitivity analysis using enrollments post–April 2012, 
when there was substantial virus co-circulation, demonstrated 
Table 2. Number and Percent of FLU003 Inpatients Enrolled From the ICU
A(H1N1)pdm09 A(H3N2) B
No. % No. % No. % P Valuea
Enrolled before October 2013 93 21.1 30 15.6 12 17.1 .24
Enrolled after October 2013 37 18.4 30 8.8 10 6.5 .0003
Overall 130 20.3 60 11.3 22 9.8 <.0001
Abbreviation: ICU, intensive care unit.
aChi-square test.
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similar findings to those enrolled over 6 years. The percentages 
of outpatients who were subsequently hospitalized were 2.0%, 
0.9%, and 2.1% for A(H1N1)pdm09, A(H3N2), and B, respec-
tively (P  =  .03). Compared with A(H1N1)pdm09, the unad-
justed ORs of progressing to death or hospitalization were 0.42 
for outpatients with A(H3N2) (95% CI, 0.19–0.92; P = .03) and 
1.03 (95% CI, 0.49–2.14; P = .94) for patients with B. The OR for 
A(H3N2) vs B was 0.41 (95% CI, 0.19–0.88; P = .02).
A second sensitivity analysis was performed including sites 
that enrolled one or more outpatients with each type/subtype. 
In 3416 patients with 61 outcomes, the OR of A(H3N2) vs 
A(H1N1)pdm09 was 0.23 (95% CI, 0.12–0.45; P <  .0001), for 
B vs A(H1N1)pdm09 it was 0.68 (95% CI, 0.37–1.25; P = .21), 
and for A(H3N2) vs B it was 0.34 (95% CI, 0.16–0.72; P = .004).
FLU003 Inpatient Cohort Day-60 Composite Outcomes
Day 60 disease progression outcomes were known for 1291 
(92.3%) inpatients (Supplementary Figure S2): The percentage 
with a composite outcome did not vary by virus (Table 4). This 
was observed overall (P =  .32) and for ICU (P =  .80) or ward 
(P = .39) enrollments. With considerations of the components 
of the composite outcome, there was no difference in the num-
ber of patients transferred to the ICU from the ward (P = .24) 
while there was a trend toward more patients with A(H1N1)
pdm09 having an extended (≥28 days) hospitalization (P = .07); 
the percentage dying within 60  days was 7.1% for A(H1N1)
pdm09, 5.0% for A(H3N2), and 7.3% for B (P = .30). Of the 82 
deaths, 64 (78.0%) occurred during the enrollment hospitaliza-
tion. Mortality was higher in ICU (24.3%) than general ward 
enrollments (3.0%; P < .001).
Compared with A(H1N1)pdm09 virus-infected inpa-
tients, the adjusted ORs of death, hospitalization ≥28  days, 
ICU admission, or use of mechanical ventilation were 0.87 
for A(H3N2) (95% CI, 0.52–1.44; P =  .59) and 1.00 (95% CI, 
0.57–1.75; P  =  1.00) for influenza B; the OR for A(H3N2) vs 
B was 0.87 (95% CI, 0.48–1.56; P = .64) (Table 5). In analyses 
based on seasons post–April 2012 when all viruses were co-cir-
culating, the adjusted ORs of death, hospitalization ≥28 days, 
ICU admission, or use of mechanical ventilation were 1.08 
for A(H3N2) vs A(H1N1) (95% CI, 0.57–2.06; P  =  .82), 1.28 
for B vs A(H1N1) (95% CI, 0.65–2.55; P  =  .47), and 0.84 
(95% CI, 0.46–1.54; P =  .57) for A(H3N2) vs B. Of covariates 
Table 3. Composite Outcome at 14 Days in the FLU002 Outpatient Cohort According to Influenza Virus Type/Influenza A Virus Subtype
A(H1N1)pdm09
(n = 1235)
A(H3N2)
(n = 1785) B (n = 767)
No. % No. % No. % P Valuea
Death 1 0.1 0 0.0 0 0.0
Hospitalization 41 3.3 13 0.7 17 2.2 <.0001
Death or hospitalization 42 3.4 13 0.7 17 2.2 <.0001
aTwo degrees of freedom chi-square test.
Table 4. Composite Outcome at 60 Days in the FLU003 Inpatient Cohort According to Influenza Virus Type/Influenza A Virus Subtype
A(H1N1)pdm09 A(H3N2) B
No. %· No. % No. % P Valuea
Enrollment From General Ward n = 467 n = 441 n = 185
Composite outcomeb 54 11.6 39 8.8 18 9.7 .39
Death 15 3.2 11 2.5 7 3.8 .65
Extended hospitalizationc 23 4.5 17 3.6 5 2.5 .42
Transfer to ICUd 30 5.9 17 3.6 11 5.4 .24
Enrollment from ICU n = 120 n = 58 n = 20
Composite outcomeb 58 48.3 25 43.1 9 45.0 .80
Death 27 22.1 14 23.7 8 38.1 .29
Extended hospitalizationc 37 29.·6 11 18.6 3 14.3 .14
Overall n = 587 n = 499 n = 205
Composite outcomeb 112 19.1 64 12.8 27 13.2 .32
Death 42 7.1 25 5.0 15 7.3 .30
Extended hospitalizationc 60 9.5 28 5.3 8 3.6 .07
Abbreviation: ICU, intensive care unit.
aTwo degrees of freedom chi-square test. Overall is stratified by ward at enrollment.
bDeath, extended hospitalization, or progression to ICU or mechanical ventilation.
cHospitalized for ≥28 days after enrollment.
dIf enrolled from the general ward, progression to ICU or mechanical ventilation.
Downloaded from https://academic.oup.com/ofid/article-abstract/4/4/ofx212/4372244
by Kobenhavns Universitets user
on 14 May 2018
6 • OFID • Dwyer et al
considered in the adjusted analysis, in univariate analyses 
(stratified by enrollment location only), age (P < .0001), lower 
BMI (P = .003), and continent of enrollment (Europe and South 
America; P = .0009) were associated with an increased risk of 
disease progression over the 60-day follow-up. Virus differences 
in the composite outcome and in death were consistent among 
subgroups defined by age, continent of enrollment, presence of 
comorbidities, and complications (Tables S4 and S5).
DISCUSSION
In these 2 large international cohort studies of adults with labo-
ratory-confirmed influenza, outpatients with A(H1N1)pdm09 
were more likely to be hospitalized within 14 days than those 
with A(H3N2) or influenza B.  Although hospitalized adults 
with A(H1N1)pdm09 were more likely to have severe influ-
enza as measured by the percentage of ICU enrollments, dif-
ferences in disease progression or mortality at 60-day follow-up 
were not detected. Notably, both outpatients and hospitalized 
patients with A(H3N2) or B had more comorbidities than those 
with A(H1N1)pdm09, and patients with A(H1N1)pdm09 were 
younger.
Among outpatients, the 14-day hospitalization risk was low-
est for those with influenza A(H3N2). The percentage of out-
patients with A(H3N2) subsequently hospitalized was 0.7%, 
compared with 3.4% and 2.2% for A(H1N1)pdm09 and B, 
respectively. The lower A(H3N2) hospitalization risk persisted 
after adjustment for age and other covariates, when analyses 
were done over influenza seasons with substantial virus co-cir-
culation and for sites that enrolled at least 1 patient of each type/
subtype. The finding was also consistent for subgroups defined 
by age, continent of enrollment, and presence of comorbidities. 
Our results differ from studies that examined hospitalization 
within 30  days among enrollments in vaccine effectiveness 
studies in Wisconsin [5,6]. The differences may relate to vari-
ations in sample size and statistical power, the study time peri-
ods, inclusion of children, outcome definitions, or unmeasured 
confounders. In Belongia et  al. [6], 6/150 (4.0%) adults with 
A(H1N1)pdm09 were hospitalized within 30  days of onset 
(contrasting with 14-day follow-up in FLU002) vs 17/377 
(4.5%) for A(H3N2). However, outpatients with A(H1N1)
pdm09 were enrolled in 2009, and those with A(H3N2) were 
enrolled in 2007–2008 (influenza B patients were not ana-
lyzed) [6], whereas we enrolled adults continuously from 2009 
through 2015.
In FLU003, similar to US Centers for Disease Control and 
Prevention (CDC) studies [2, 3], we found that inpatients with 
A(H1N1)pdm09 were more likely to be admitted to the ICU. 
Although more A(H1N1)pdm09 inpatients were enrolled from 
the ICU (and the percentage transferring to the ICU from the 
general ward was higher), this difference was not significant. 
If ICU enrollment and transfer from the ward are considered 
together, A(H1N1)pdm09 virus infection appeared to be asso-
ciated with more severe disease.
The observation of increased severity of hospitalization 
with A(H1N1)pdm09 virus infection was not supported by 
the 60-day follow-up. Disease progression did not vary among 
types/subtypes irrespective of general ward or ICU enrollment. 
Furthermore, in neither the CDC studies [2, 6] nor FLU003 was 
there evidence of mortality differences among types/subtypes. 
In Chaves et al. [2], the percentages of patients dying before hos-
pital discharge were 3.7%, 3.9%, and 4.1%, for A(H1N1)pdm09, 
A(H3N2), and influenza B, respectively. In FLU003 inpatients, 
the corresponding percentages for death within 60  days were 
7.1% (A(H1N1)pdm09), 5.0% (A(H3N2)), and 7.3% (B). Two 
other studies have reported mortality by virus type/subtype. 
Loubet et al. [4] reported that the percentage of patients dying 
during hospitalization did not vary by type/subtype (A(H1N1)
pdm09 2%, A(H3N2) 4%, influenza B 4%), but the total number 
of deaths (n = 20) was much smaller than in FLU003 (n = 82) 
or Chaves et al. (n = 109) [2]. Similarly, in Hong Kong mortality 
was compared for adults hospitalized with influenza A vs B in 
2007–2008 and found not to differ: 21/414 (5%) with A(H3N2) 
Table 5. Unadjusted and Adjusted Odds Ratios Disease Progression in the FLU003 Inpatient Cohort by Influenza Virus Type/Influenza A Virus Subtype
A(H3N2) vs A(H1N1)pdm09 B vs A(H1N1)pdm09 A(H3N2) vs B
Enrolled From General Ward OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Unadjusteda 0.74 0.48–1.15 .18 0.82 0.47–1.45 .50 0.90 0.50–1.62 .73
Adjustedb 0.79 0.44–1.43 .43 0.95 0.49–1.84 .89 0.83 0.43–1.59 .57
Enrolled from ICU
Unadjusteda 0.81 0.43–1.52 .51 0.87 0.34–2.26 .78 0.93 0.33–2.57 .88
Adjustedb 0.11 0.38–3.25 .85 1.06 0.30–3.83 .92 1.05 0.25–4.45 .95
Total
Unadjusteda 0.76 0.53–1.09 .14 0.84 0.52–1.36 .48 0.91 0.55–1.51 .71
Adjustedb 0.87 0.52–1.44 .59 1.00 0.57–1.75 1.00 0.87 0.48–1.56 .64
Abbreviations: CI, confidence interval; ICU, intensive care unit; OR, odds ratio.
aOverall is stratified by hospital unit at enrollment.
bStratified by hospital unit at enrollment and adjusted for region, age, gender, ethnicity, body mass index, smoking, duration of symptoms, ≥1 comorbidities, ≥1 severe complications, 
influenza vaccine in past year, and use of antivirals on or before enrollment date.
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vs 13/215 (6%) with influenza B [9]. It is uncertain why outpa-
tients with A(H1N1)pdm09 were more likely to be hospitalized, 
but hospitalized A(H1N1)pdm09-infected patients did not 
have worse 60-day outcomes (despite being more likely to be 
enrolled from the ICU). One explanation may be that younger 
adults hospitalized with A(H1N1)pdm09 virus infection, 
although less likely to have comorbidities, were more likely to 
be admitted to the ICU if complications were present.
Strengths of our study include concurrent, prospective 
enrollment of both outpatients and inpatients from multiple 
countries in both hemispheres over 6 years. A defined follow-up 
period for assessing outcomes was used with a high proportion 
of follow-up evaluation, and common protocols were used for 
sample collection and laboratory testing. Limitations include 
adults-only enrollment and a relatively small number of disease 
progression outcomes in the outpatient cohort, thereby limiting 
power, an issue identified for many studies [10].
In summary, the findings from these global follow-up stud-
ies illustrate the benefit of planned prospective observational 
studies to complement influenza surveillance approaches. Such 
studies are critical for assessing predictors of disease progression 
including the changing severity among types/subtypes over time.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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